Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

DBV Technologies

0QAJ
Current price
0.74 EUR +0.01 EUR (+1.37%)
Last closed 0.74 USD
ISIN US23306J1016
Sector Healthcare
Industry Biotechnology
Exchange London Exchange
Capitalization 86 462 808 USD
Yield for 12 month -74.08 %
1Y
3Y
5Y
10Y
15Y
0QAJ
21.11.2021 - 28.11.2021

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France. Address: 177-181 Avenue Pierre Brossolette, Montrouge, France, 92120

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

5.33 USD

P/E ratio

Dividend Yield

Current Year

+15 728 000 USD

Last Year

+4 800 000 USD

Current Quarter

+1 161 000 USD

Last Quarter

+1 407 000 USD

Current Year

+20 225 000 USD

Last Year

-16 534 000 USD

Current Quarter

-2 994 999 USD

Last Quarter

-3 057 000 USD

Key Figures 0QAJ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -79 693 000 USD
Operating Margin TTM -2914.9 %
PE Ratio
Return On Assets TTM -34.89 %
PEG Ratio
Return On Equity TTM -72.64 %
Wall Street Target Price 5.33 USD
Revenue TTM 13 814 000 USD
Book Value 0.82 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -49.3 %
Dividend Yield
Gross Profit TTM 4 844 000 USD
Earnings per share -0.91 USD
Diluted Eps TTM -0.91 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics 0QAJ

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 0QAJ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:2
Payout Ratio
Last Split Date 07.06.2024
Dividend Date

Stock Valuation 0QAJ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM 6.2591
Enterprise Value EBITDA -2.0735
Price Book MRQ 0.9732

Financials 0QAJ

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 0QAJ

For 52 weeks

0.5 USD 3.2 USD
50 Day MA 0.88 USD
Shares Short Prior Month 307 050
200 Day MA 1.35 USD
Short Ratio 6.82
Shares Short 293 693
Short Percent 0.39 %